

June 03, 2025

To,  
National Stock Exchange of India Limited  
Exchange Plaza  
Bandra Kurla Complex,  
Bandra (E), Mumbai - 400 051  
(SYMBOL: THYROCARE)

BSE Limited  
Phiroze Jeejeeboy Towers  
Dalal Street,  
Mumbai- 400 001  
(SCRIP CODE 539871)

**Sub: Disclosure under Regulation 30 – Additional Capital infusion in Thyrocare Laboratories (Tanzania) Limited**

**Dear Sir/Madam,**

This is in reference to our earlier communications dated September 19, 2023, December 03, 2024, and March 03, 2025, regarding the establishment and investment in Thyrocare Laboratories (Tanzania) Limited (“Thyrocare Tanzania”). Thyrocare Tanzania operates in the diagnostic and healthcare services sector and is a joint venture between Thyrocare Technologies Limited (“Thyrocare India” or “the Company”) and the Kastipharm Group, comprising Kastipharm Limited, Mr. Anwar Alnoor Kachra and Mr. Joseph Philemon Mgaya.

As on date, the shareholding in Thyrocare Tanzania stands at 57.25% held by Thyrocare India and 42.75% by the Kastipharm Group. Accordingly, Thyrocare Tanzania is a subsidiary of the Company.

We wish to inform you that on June 03, 2025, the Company has made an additional investment of USD 175,000 (equivalent to INR 1,49,88,750) in Thyrocare Tanzania by subscribing to Compulsorily Convertible Irredeemable Preference Shares (CCPS).

The details, as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), read with SEBI Master Circular dated November 11, 2024 (Reference No. SEBI/HO/CFD/PoD2/CIR/P/0155), are provided in the statement attached as “Annexure A”.

We request you to kindly take this on record.

Yours Faithfully

**For Thyrocare Technologies Limited**



**Brijesh Kumar**  
Company Secretary and Compliance Officer

### Annexure A

Sr	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.	<p><b>Name:</b> Thyrocare Laboratories (Tanzania) Limited (“Thyrocare Tanzania”)</p> <p>Brief details of Thyrocare Tanzania:</p> <ul style="list-style-type: none"> <li>• <b>Turnover:</b> INR 1 Crore for the year ended March 31, 2025. (Operations commenced in April 2024).</li> <li>• <b>Net-worth:</b> INR 2.09 Crores as on March 31, 2025</li> <li>• <b>Authorised Capital:</b> 10,00,000, ordinary shares of face value of 10,000 Tanzania Shillings each.</li> </ul>
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm's length”	<p>Yes, the investment by subscribing of Compulsorily Convertible Irredeemable Preference Shares (“CCPS”) of Thyrocare Tanzania is a related party transaction.</p> <p>Save and except aforementioned, the promoters/promoter group are not otherwise interested.</p> <p>The transaction has been carried out at arm's length.</p>
3.	Industry to which the entity being acquired Belongs	Healthcare Services
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity	<p>The capital infusion in Thyrocare Tanzania has been made to facilitate its business operations and working capital requirements.</p> <p>Thyrocare Tanzania's business is similar to the Company's main line of business viz. diagnostic and healthcare services.</p>
5.	Brief details of any governmental or regulatory approvals required for the acquisition	<p>Not Applicable.</p> <p>Necessary filings and/or reporting will be made as per applicable laws.</p>

6.	Indicative time period for completion of the Acquisition	<p>As per the approval of the Company's Board, a total investment of up to INR. 15 Crores can be made by the Company in one or more tranches, in Thyrocare Tanzania from time to time, based on business requirements.</p> <p>The total investment made by the Company till date (including this tranche of USD 175,000) amounts to USD 675,020 (equivalent to INR 5,68,70,914).</p> <p>The remaining capital infusion will be made by the Company in one or more tranches, depending on Thyrocare Tanzania's business requirements.</p>									
7.	Consideration - whether cash consideration or share swap or any other form and details of the Same	Cash Consideration									
8.	Cost of acquisition and/or the price at which the shares are acquired	Total investment till date: USD 675,020 (equivalent to INR 5,68,70,914), including the current investment of USD 175,000.									
9.	Percentage of shareholding / control acquired and / or number of shares acquired	<p>The percentage of shareholding of the Company in Thyrocare Tanzania is as follows:</p> <table border="1"> <thead> <tr> <th>Securities</th><th>Existing % of Holding</th><th>Post-Allotment % of Holding</th></tr> </thead> <tbody> <tr> <td>Equity Shares</td><td>57.25%</td><td>57.25%</td></tr> <tr> <td>CCPS</td><td>0.00%</td><td>100.00%</td></tr> </tbody> </table>	Securities	Existing % of Holding	Post-Allotment % of Holding	Equity Shares	57.25%	57.25%	CCPS	0.00%	100.00%
Securities	Existing % of Holding	Post-Allotment % of Holding									
Equity Shares	57.25%	57.25%									
CCPS	0.00%	100.00%									
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>Thyrocare Tanzania is a company incorporated in the Republic of Tanzania, with Registration Number 168657943, dated September 19, 2023, and operates in the diagnostic and healthcare services sector.</p> <p>The turnover for the financial year ended March 31, 2025, is provided in Point 1 of this table. As Thyrocare Tanzania is a newly incorporated entity, the turnover history for the last three years is not applicable.</p>									